NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $0.88 -0.09 (-9.04%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$0.91 +0.03 (+2.89%) As of 05/19/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rani Therapeutics Stock (NASDAQ:RANI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Rani Therapeutics alerts:Sign Up Key Stats Today's Range$0.88▼$0.9750-Day Range$0.73▼$1.3852-Week Range$0.39▼$3.87Volume1.28 million shsAverage Volume821,183 shsMarket Capitalization$109.39 millionP/E RatioN/ADividend YieldN/APrice Target$8.75Consensus RatingModerate Buy Company Overview Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones. Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. In addition to its insulin candidate, the company is exploring oral formulations of GLP-1 receptor agonists and other therapeutic proteins. Rani has secured investigational new drug (IND) approvals and completed initial safety and pharmacokinetic assessments in humans, positioning its RaniPill platform for broader application across multiple chronic disease areas. Headquartered in San Jose, California, Rani Therapeutics leverages collaborations with research institutions and industry partners to streamline development and manufacturing. While still in the clinical stages, the company is preparing for pivotal trials and regulatory interactions to support future commercialization. Rani’s management team combines expertise from pharmaceutical development, medical device engineering and regulatory affairs, underscoring its commitment to transforming biologic drug delivery and expanding patient access globally.AI Generated. May Contain Errors. Read More Rani Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreRANI MarketRank™: Rani Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 376th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingRani Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialRani Therapeutics has a consensus price target of $8.75, representing about 889.4% upside from its current price of $0.88.Amount of Analyst CoverageRani Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rani Therapeutics are expected to grow in the coming year, from ($0.24) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rani Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.84% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 13.57, which indicates bearish sentiment.Change versus previous monthShort interest in Rani Therapeutics has recently decreased by 5.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentRani Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Rani Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RANI on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows4 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.73% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RANI Stock News HeadlinesRani Therapeutics Faces Nasdaq Bid Price Noncompliance NoticeMay 17 at 9:32 AM | theglobeandmail.comNasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid PriceMay 17 at 2:11 AM | tipranks.comI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement. | Porter & Company (Ad)Rani Therapeutics (NASDAQ:RANI) Stock Rating Upgraded by Wall Street ZenMay 17 at 1:20 AM | americanbankingnews.comRani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO TransitionMay 15, 2026 | globenewswire.comRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceMay 12, 2026 | globenewswire.comRani Therapeutics (RANI) Expected to Announce Earnings on WednesdayMay 11, 2026 | americanbankingnews.comThis Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearMay 9, 2026 | finance.yahoo.comSee More Headlines RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $1.35 at the beginning of the year. Since then, RANI stock has decreased by 34.5% and is now trading at $0.8844. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its earnings results on Friday, May, 15th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. The firm earned $1.71 million during the quarter, compared to analyst estimates of $1.13 million. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an initial public offering on Thursday, July 29th 2021. The company issued 6,666,667 shares at $14.00-$16.00 per share. Who are Rani Therapeutics' major shareholders? Top institutional investors of Rani Therapeutics include Kestra Private Wealth Services LLC (0.21%). Insiders that own company stock include South Cone Investments Limited, Mir A Imran, Talat Imran, Kate Mckinley and Cortes Isidoro Alfonso Quiroga. View institutional ownership trends. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rani Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO). Company Calendar Last Earnings5/15/2026Today5/19/2026H.C. Wainwright 4th Annual BioConnect Investor Conference5/19/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RANI's financial health is in the Red zone, according to TradeSmith. RANI has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RANI CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees110Year Founded2012Price Target and Rating Average Price Target for Rani Therapeutics$8.75 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+889.4%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.67 million Net MarginsN/A Pretax Margin-1,143.17% Return on Equity-206.46% Return on Assets-83.95% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio4.21 Sales & Book Value Annual Sales$1.63 million Price / Sales67.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.29 per share Price / Book3.05Miscellaneous Outstanding Shares123,690,000Free Float90,629,000Market Cap$109.39 million OptionableOptionable Beta0.74 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:RANI) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
